Product Program year 2020 Source: CMS Open Payments

Zoladex

Drug Oncology

NDC 0310-0950-36

Open in the dashboard

General payments

$75,886

1,378 payments

Research payments

$638

2 payments

Through program year 2020, $75,886 in general payments and $638 in research payments were reported against Zoladex (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $12,215 126
2020 Research $425 1
2019 General $63,671 1,252
2019 Research $213 1

Breakdown

Who paid General payments · program years 2019–2020
  1. TerSera Therapeutics LLC $73,226 1,377 payments
  2. AstraZeneca UK Limited $2,660 1 payment
Top recipients General payments · program year 2020
  1. Joseph Bailes McKinney, TX $6,948 57% · 2 payments
  2. Neal Shore Urology · Myrtle Beach, SC $2,660 22% · 1 payment
  3. Shagufta Naqvi Medical Oncology · Katy, TX $165 1% · 13 payments
  4. Worood Abboud Hematology & Oncology · Joliet, IL $96 <1% · 2 payments
  5. Shaker Dakhil Hematology & Oncology · Wichita, KS $73 <1% · 3 payments

The top 5 of 97 recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Urology $2,660 52% · 1 practitioner
  2. Hematology & Oncology Internal Medicine $1,521 29% · 60 practitioners
  3. Medical Oncology Internal Medicine $670 13% · 20 practitioners
  4. Radiation Oncology Radiology $98 2% · 2 practitioners
  5. Internal Medicine $75 1% · 4 practitioners

The top 5 of 10 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. Texas $7,501 61% · 15 recipients
  2. South Carolina $2,660 22% · 1 recipient
  3. California $534 4% · 16 recipients
  4. Florida $359 3% · 14 recipients
  5. Kansas $214 2% · 6 recipients

The top 5 of 22 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

179

Prescriptions dispensed, refills included

Drug cost

$189,356

Paid at the pharmacy, in all

Prescribers

13

With 11 or more claims of it

Medicare Part D drugs matched to ZOLADEX, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Zoladex Goserelin Acetate Same name 13 179 $189,356

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 13 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Rachel Raab Hematology-Oncology NC 24 $21,543 $71
Christine Simone Hematology-Oncology FL 17 $16,012 $15
Eddiemar Ortiz Cruz Hematology-Oncology PR 15 $14,568 None on record
Jen Wang Internal Medicine NY 14 $20,462 None on record
Andrew Adair Family Practice MI 13 $13,342 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 13 in the dashboard with a free account
1,378 general · 2 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record